ONY846323

ONY846323 is an investigational drug candidate being developed by ONY Biotech for the treatment of neonatal respiratory conditions. As of early 2024, the candidate is in the preclinical stage of development. ONY Biotech is a specialty pharmaceutical company that focuses on neonatology, particularly surfactant replacement therapies and respiratory management for critically ill newborns. While the company's flagship product is Infasurf (calfactant), specific details regarding the molecular target, modality, or chemical structure of ONY846323 have not been publicly disclosed in their pipeline communications. It is part of a suite of internal candidates (including ONY296615 and ONY604123) aimed at expanding therapeutic options within the neonatal intensive care unit (NICU).